Chronic low back pain (CLBP) is a pervasive health issue affecting millions worldwide, often leading to reduced quality of life, missed workdays, and substantial healthcare costs. For those living with persistent discomfort, finding safe, effective, and non-pharmacological treatments is a top priority. Recent research highlights two promising therapies—infrared (IR) therapy and photobiomodulation therapy (PBMT)—that offer relief without the side effects of medications or the risks of invasive procedures. Let’s dive into the science behind these treatments and how they’re transforming low back pain management.
Understanding the Burden of Chronic Low Back Pain
Chronic low back pain, defined as pain lasting more than three months, is a leading cause of disability globally. It impacts approximately 80% of adults at some point in their lives and accounts for a significant portion of healthcare consultations and missed work. For nursing professionals, in particular, the risk is even higher due to the physical demands of their jobs, such as lifting patients and maintaining awkward postures. Traditional treatments like nonsteroidal anti-inflammatory drugs (NSAIDs) or surgery often come with drawbacks, including side effects or long recovery times, making alternative therapies increasingly appealing.
Infrared Therapy: Targeted Pain Relief with Proven Results
Infrared therapy uses specific wavelengths of light to penetrate deep into tissues, promoting healing and reducing pain. A randomized controlled trial published in Pain Research and Management (PMC2539004) tested the efficacy of a portable IR therapy device on 40 patients with chronic low back pain lasting over six years. The device, which emits IR energy at 800–1200 nm and is FDA-registered as a therapeutic device, was worn as a waistband powered by rechargeable batteries.
Over seven weekly sessions, the treatment group experienced a significant reduction in pain, with their mean Numerical Rating Scale (NRS) scores dropping from 6.9 to 3 out of 10. In contrast, the placebo group (using identical devices without power) only saw a modest decrease from 7.4 to 6 out of 10. Importantly, no adverse effects were reported, and the therapy was found to be safe thanks to an automatic shut-off feature that prevents overheating above 42°C. The study concluded that IR therapy is not only effective but also convenient for prolonged use, as the portable design allows patients to remain active during treatment.
Photobiomodulation Therapy: Low-Cost, Long-Lasting Relief
Photobiomodulation therapy (PBMT), also known as low-level laser therapy, uses light energy to modulate biological processes, reduce inflammation, and alleviate pain. A study published in Revista Brasileira de Medicina do Trabalho (PMC9904826) focused on the cost-effectiveness of systemic PBMT for nursing professionals with chronic low back pain. The therapy involved 10 sessions using a portable laser device (660 nm wavelength, 100 mW power) applied to the left radial artery for 30 minutes per session.
The results were striking: the average cost per session was just R$25.30 (approximately USD 5), making PBMT far more affordable than alternatives like electroacupuncture (US$461.50 per patient) or NSAIDs (US$497.80 per patient). Labor costs accounted for 66% of the total expense, while the laser equipment itself contributed only 2.8%. Beyond cost savings, PBMT offers the added benefit of convenience—treatments can be administered at the workplace, reducing absenteeism, which is a major concern for both employees and employers.
Another randomized controlled trial in Journal of Lasers in Medical Sciences (PMC7118512) further validated PBMT’s effectiveness. Forty patients with chronic low back pain were divided into two groups: one receiving 12 sessions of active IR laser therapy (808 nm wavelength, 160 mW power) plus naproxen, and the other receiving sham laser therapy plus naproxen. After one month, both groups reported pain reduction, but the active laser group maintained significant improvements in pain, functional status, and spinal range of motion for three months. In contrast, the sham group’s benefits faded, with pain levels returning to baseline. Additionally, the active laser group required less rescue medication, resulting in fewer side effects.
The Science Behind the Relief: Targeting Inflammation
While the clinical benefits of PBMT are clear, researchers are still exploring its underlying mechanisms. A protocol for a randomized placebo-controlled trial published in Medicine (PMC6485775) aims to investigate how PBMT modulates inflammatory mediators in patients with chronic non-specific low back pain. Inflammatory markers like prostaglandin E₂ (PGE₂), tumor necrosis factor alpha (TNF-α), and interleukin 6 (IL-6) are known to contribute to pain and inflammation in musculoskeletal disorders.
The study will enroll 18 patients, randomizing them to receive either active PBMT (total dose of 220.05 J) or placebo. Blood samples will be collected before and 15 minutes after treatment to measure changes in inflammatory mediators, along with pain intensity ratings. If successful, this research will provide critical insights into how PBMT works at a biological level, potentially helping to tailor treatments for patients with specific inflammatory profiles.
Who Can Benefit?
Both IR therapy and PBMT are ideal for patients seeking non-pharmacological, non-invasive alternatives for chronic low back pain. They are particularly well-suited for:
- Nursing professionals and other workers with occupation-related low back pain.
- Patients who cannot tolerate NSAIDs or other pain medications.
- Individuals looking to avoid surgery or reduce reliance on invasive procedures.
- Those seeking long-lasting relief with minimal side effects.
However, as with any treatment, there are contraindications. IR therapy should be avoided in patients with malignant hyperthermia or scleroderma, while PBMT may not be suitable for those with severe skin diseases or a history of spinal surgery. Always consult a healthcare provider before starting a new therapy.
Conclusion
Infrared therapy and photobiomodulation therapy represent exciting advancements in chronic low back pain management. Backed by rigorous clinical research, these treatments offer safe, effective, and cost-efficient alternatives to traditional approaches. Whether you’re a healthcare professional struggling with work-related pain or an individual seeking long-term relief, IR therapy and PBMT are worth exploring. As research continues to uncover their mechanisms of action and expand their applications, these therapies are poised to become mainstays in the fight against chronic low back pain.
If you’re ready to take control of your pain, talk to your healthcare provider about whether IR therapy or PBMT is right for you. With their proven track records and minimal risks, they just might be the solution you’ve been searching for.
References
- Gale, G. D., Rothbart, P. J., & Li, Y. (2006). Infrared therapy for chronic low back pain: A randomized, controlled trial. Pain Research and Management, 11(3), 193–196. https://pmc.ncbi.nlm.nih.gov/articles/PMC2539004/
- Inocêncio, T. S. C., Andraus, R. A. C., Ferrari, R. A. P., Nogueira, D. N. G., Tokushima, T., & Cardelli, A. A. M. (2023). Systemic photobiomodulation in nursing professionals with chronic low back pain. Revista Brasileira de Medicina do Trabalho, 20(3), 387–392. https://pmc.ncbi.nlm.nih.gov/articles/PMC9904826/
- Kholoosy, L., Elyaspour, D., Akhgari, M. R., Razzaghi, Z., Khodamardi, Z., & Bayat, M. (2020). Evaluation of the therapeutic effect of low level laser in controlling low back pain: A randomized controlled trial. Journal of Lasers in Medical Sciences, 11(2), 120–125. https://pmc.ncbi.nlm.nih.gov/articles/PMC7118512/
- Tomazoni, S. S., Costa, L. O. P., Joensen, J., Stausholm, M. B., Naterstad, I. F., Leal-Junior, E. C. P., & Bjordal, J. M. (2019). Effects of photobiomodulation therapy on inflammatory mediators in patients with chronic non-specific low back pain: Protocol for a randomized placebo-controlled trial. Medicine, 98(15), e15177. https://pmc.ncbi.nlm.nih.gov/articles/PMC6485775/